市場調査レポート
商品コード
1140674
化学療法誘発性末梢神経障害治療の世界市場-2022-2029Global Chemotherapy Induced Peripheral Neuropathy Treatment Market - 2022-2029 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
化学療法誘発性末梢神経障害治療の世界市場-2022-2029 |
出版日: 2022年10月20日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
|
研究開発の継続的な増加は、予測期間中、市場の成長を支え続けるでしょう。
化学療法誘発性末梢神経障害市場で事業を展開している企業は、化学療法を管理するための効率的な薬剤や薬物の開発を常に行っています。体内のがん細胞は、末梢神経障害のために少量の薬剤を投与することを重要視しています。したがって、今後、世界の化学療法誘発性末梢神経障害市場の主要な市場プレーヤーは、彼らの腫瘍学的研究投資を増強しています。例えば、2021年12月、Paxman KTPは、化学療法の副作用CIPNを防ぐための新しいデバイスを作成しました。ハダースフィールド大学とPaxmanは、化学療法誘発性末梢神経障害(CIPN)を予防する医療用冷却システムの開発で提携しました。CIPNは、化学療法を受ける患者の手足に進行性で、しばしば回復不可能な痛みや過敏症を引き起こし、治療の遅れや中止を招きます。
また、研究機関との連携が世界市場の成長を後押ししています。ハーバード・ヘルス・レビューでは、神経障害の管理・治療に関する関連シグナルを提供しています。多数の化学療法誘発性末梢神経障害市場企業が、ハーバードの研究友好団体と協力し、共同研究の恩恵を受けることが期待されます。ハーバード大学医学部の洞察は、すでに多数の企業、研究ユニット、化学療法誘発性末梢神経障害のスタンドの性質とウロパチーに役立っています。
しかし、治療に伴う副作用は、世界の化学療法誘発性末梢神経障害市場の妨げになる可能性があります。
予測期間を通じて、北米が世界市場を独占しています。
本調査では、地域別に、北米、欧州、アジア太平洋、南米、中東・アフリカなどの世界市場における化学療法誘発性末梢神経障害市場を分析しています。
北米は世界の化学療法誘発性末梢神経障害市場を独占しており、予測期間中もその地位を維持すると見られています。米国は、2022年の北米の化学療法誘発性末梢神経障害治療市場に貢献しています。さまざまながんの発生率や有病率の増加により、抗がん剤の需要が高まっています。この成長は、免疫療法薬や標的療法薬など、末期に使用される他の治療オプションと比較して、より早いがん治療段階での化学療法によるものです。
アジア太平洋地域は、予測期間中に化学療法誘発性末梢神経障害市場で大幅に成長すると推定されます。この成長は、同地域におけるヘルスケアインフラの急速な発展や啓蒙活動の高まりに起因すると考えられます。さらに、インド、中国、シンガポール、マレーシアなどの新興諸国における医療観光の成長も、世界の化学療法誘発性末梢神経障害市場にプラスの影響を与えると推定されます。
化学療法誘発性末梢神経障害市場は、非常に競争が激しい市場です。世界市場の成長市場に貢献している化学療法誘発性末梢神経障害治療薬の主要プレイヤーには、Regency Pharmaceuticals、Nemus Bioscience Inc、PledPharma、Immune PharmaceIncnc.、DermaXon LLCが含まれます。大手企業は、化学療法誘発性末梢神経障害市場の世界の成長のために、新製品の上市と拡大戦略を採用しています。2022年3月、旭化成ファーマは、ART-123(一般名:トロンボモジュリンアルファ、日本での販売名:レコモジュリン注)の化学療法誘発性末梢神経障害(CIPN)予防の日米国際第1相試験の最初の患者に対する薬剤投与試験の開始を発表しました。本試験は、旭化成株式会社の100%子会社であるVeloxis Pharmaceuticals, Inc.と共同で実施します。2021年9月、ノバレッドは、慢性疼痛を適応症とする非オピオイド治療薬候補のパイプラインを拡充するため、メティス社(Metys Pharmaceuticals)を買収しました。この買収は、効果的で忍容性の高い薬剤を患者さんにお届けすると同時に、非中毒性治療薬に対する緊急のニーズに対応することを目的としています。
COVID-19の影響世界の化学療法誘発性末梢神経障害市場にネガティブな影響を与えます。
COVID-19の発生は、世界の化学療法誘発性末梢神経障害市場に確実に影響を与えています。ロックダウンは、新しい癌症例の診断を強制し、その結果、COVID-19流行の中で化学療法誘発性末梢神経障害治療の採用率を頓挫させたからです。したがって、化学療法誘発性末梢神経障害市場は、2020年にかなりの減少を予見しています。
Chemotherapy-Induced Peripheral Neuropathy Treatment Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 5 % during the forecast period (2022-2029).
Chemotherapy-induced peripheral neuropathy is a serious clinical problem induced by several chemotherapeutics drugs or cytotoxic drugs such as platinum, taxanes, and vinca alkaloids eribulin, epothilones, and bortezomib. These drugs cause different pathological problems to the neurons. The pathological problems lead to the degeneration of peripheral sensory and motor nerves and cause patients to present with sensory disturbances, balance problems, or weakness. The technological advancement in the treatment and diagnosis of cancer and the rising incidence of chemotherapy-induced peripheral neuropathy is expected to propel the market growth. Moreover, the increasing demand for cost-efficient therapeutics in emerging regions is an opportunity for market growth.
Market Dynamics: Continuous rise in R&D will continue supporting the growth of the market during the forecast period.
The companies operating in the chemotherapy-induced peripheral neuropathy market are constantly developing efficient drugs and medications to manage chemotherapy. Cancerous cells in the body make it critical to administer minor doses of drugs for peripheral neuropathy. Henceforth, the key market players in the global chemotherapy-induced peripheral neuropathy market are ramping up their oncological research investments. For instance, in December 2021, Paxman KTP created a new device to prevent chemotherapy side-effect CIPN. University of Huddersfield and Paxman partnered to develop a medical cooling system to prevent Chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes progressive and often irreversible pain or sensitivity in the hands and feet of patients undergoing chemotherapy leading to delays and discontinuation of treatment.
Also, collaboration with research institutes is driving the growth of the global market. Harvard Health Reviews have been offering relevant signals for the management and treatment of neuropathy. Numerous chemotherapy-induced peripheral neuropathy market companies are expected to collaborate with Harvard's research fraternity to reap the benefits of collaborative research. The Harvard Medical School insights have already helped numerous companies, research units, and chemotherapy-induced peripheral neuropathy'stand nature and uropathy.
However, the adverse effect associated with the treatment may hamper the global chemotherapy-induced peripheral neuropathy treatment market.
Market Segmentation: The antidepressants segment accounted for the highest share in global chemotherapy-induced peripheral neuropathy treatment market.
Antidepressant contributes the major share of the chemotherapy-induced peripheral neuropathy treatment market. It has a clinically meaningful effect on chemotherapy-induced peripheral neuropathy. Adjunct treatment options for chemotherapy-induced peripheral neuropathy include a topical analgesic, a tricyclic antidepressant, an anticonvulsant, or an SNRI. Therefore, realizing the potential benefits of chemotherapy-induced peripheral neuropathy as an antidepressant will drive market growth during the forecast period.
The chemotherapy-induced peripheral neuropathy treatment market has been classified into platinum agents, taxanes, vinca alkaloids, and others based on the application. The Platinum Agents segment held a significant market share in the global chemotherapy-induced peripheral neuropathy treatment market in the forecast period. The major application of platinum agents is the chemotherapy-induced peripheral neuropathy treatment market. Platinum agents (carboplatin, cisplatin, and oxaliplatin) are a class of chemotherapy agents with a wide range of activity against several solid tumors. Toxicity to the peripheral nervous system is the key dose-reducing toxicity of a few platinum drugs of clinical interest. Among the platinum compounds, cisplatin is considered the most neurotoxic, inducing mainly sensory neuropathy of the upper and lower extremities.
Geographical Penetration: North America dominated the global market throughout the forecast period.
Based on geography, the study analyzes the chemotherapy-induced peripheral neuropathy treatment market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America dominated the global chemotherapy-induced peripheral neuropathy treatment market and is expected to retain its position during the forecast period. The U.S. contributed over xx % to the North American chemotherapy-induced peripheral neuropathy treatment market in 2022. The increase in the incidence and prevalence rate of different cancer has led to a rise in demand for cancer drugs. This growth is due to chemotherapy in earlier cancer treatment stages compared to other therapy options such as immunological therapy drugs and targeted therapy drugs used in the late stage.
The Asia Pacific is estimated to grow considerably in the chemotherapy-induced peripheral neuropathy treatment market during the forecast period. This growth can be accredited to the rapidly developing healthcare infrastructure and rising awareness programs in this region. Further, growing medical tourism in developing countries such as India, China, Singapore, and Malaysia is also estimated to positively youth the global chemotherapy-induced peripheral neuropathy treatment market.
The chemotherapy-induced peripheral neuropathy treatment market is highly competitive. The key chemotherapy-induced peripheral neuropathy treatment players contributing to the global market's growth market include Regency Pharmaceuticals, Nemus Bioscience Inc, PledPharma, Immune PharmaceIncnc., and DermaXon LLC. The major players are adopting new product launches and expansion strategies for global growth in the chemotherapy-induced peripheral neuropathy treatment market. In March 2022, Asahi Kasei Pharma announced that a drug administration study began for the first patient in the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). This study is performed jointly with Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary of Asahi Kasei Corp. In September 2021, Novaremed acquired Metys Pharmaceuticals to expand its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications. This acquisition aims to deliver effective and well-tolerated medications to patients while simultaneously addressing the urgent need for non-addictive treatments.
COVID-19 Impact: Negative impact on the global chemotherapy-induced peripheral neuropathy treatment market.
The outbreak of COVID-19 has certainly impacted the global chemotherapy-induced peripheral neuropathy treatment market, as the lockdown has compelled the diagnosis of new cancer cases, which in turn has derailed the adoption rate of chemotherapy-induced peripheral neuropathy treatment amidst the COVID-19 pandemic. Therefore, the chemotherapy-induced peripheral neuropathy treatment market is expected to foresee a considerable decline in 2020.